Jim Mullen scours pri­vate eq­ui­ty deals amid biotech win­ter; Ex-Ab­b­Vie med­ical chief suc­ceeds Brig­gs Mor­ri­son at Syn­dax

Jim Mullen is in, by his count, his third or fourth “long, cold win­ter in biotech in­vest­ing.” But that’s not stop­ping the ex-Bio­gen CEO from find­ing flick­ers of light.

Ear­li­er this week, pri­vate eq­ui­ty play­er Ad­vent In­ter­na­tion­al an­nounced that Mullen had joined as an op­er­at­ing part­ner — its term for in­de­pen­dent ad­vi­sors who bring in­dus­try ex­pe­ri­ence.

Mullen told End­points News in an in­ter­view that he’s been do­ing ad­vis­ing work for a num­ber of pri­vate eq­ui­ty firms and en­joyed it.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters